Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier:
NCT01659944
First received: August 6, 2012
Last updated: August 7, 2012
Last verified: August 2012
  Purpose

The primary objective is to determine the effect of repeated oral doses of eliglustat 150 mg twice daily (BID) on the pharmacokinetics (PK) of orally administered metoprolol 50 mg in healthy adults.

The secondary objective is to assess the safety and tolerability of a single oral dose of metoprolol 50 mg when administered alone and in combination with repeated oral doses of eliglustat 150 mg BID in healthy adults.


Condition Intervention Phase
Healthy
Drug: Eliglustat
Drug: Metoprolol
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adult Subjects.

Resource links provided by NLM:


Further study details as provided by Genzyme, a Sanofi Company:

Primary Outcome Measures:
  • Metoprolol area under the plasma concentration time curve from time zero to the last evaluable concentration (AUC0-last) [ Time Frame: Day 1 and Day 7; predose and up to 48 hours after drug administration ] [ Designated as safety issue: No ]
  • Metoprolol area under the plasma concentration time curve from time zero extrapolated to infinity (AUC0-∞) [ Time Frame: Day 1 and Day 7; Predose and up to 48 hours after drug administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Maximum plasma concentration (Cmax) for metoprolol [ Time Frame: Day 1 and Day 7; Predose and up to 48 hours after drug administration ] [ Designated as safety issue: No ]
  • Time to maximum plasma concentration (Tmax) for metoprolol [ Time Frame: Day 1 and Day 7; Predose and up to 48 hours after drug administration ] [ Designated as safety issue: No ]
  • Terminal elimination half-life (T1/2) for metoprolol [ Time Frame: Day 1 and Day 7; Predose and up to 48 hours after drug administration ] [ Designated as safety issue: No ]
  • Trough plasma concentration of eliglustat [ Time Frame: Day 3, Day 4, Day 5, Day 6, Day 7 and Day 8. ] [ Designated as safety issue: No ]
    Eliglustat plasma concentration observed just prior to administration during repeated dosing.

  • Maximum plasma concentration (Cmax) of eliglustat [ Time Frame: Day 7, up to 12 hours after drug administration ] [ Designated as safety issue: No ]
  • Time to maximum plasma concentration (Tmax) of eliglustat [ Time Frame: Day 7; up to 12 hours after drug administration ] [ Designated as safety issue: No ]
  • Eliglustat area under the plasma concentration time curve during the dosing interval (AUC0-τ) [ Time Frame: Day 7; up to 12 hours after drug administration ] [ Designated as safety issue: No ]
  • Number of participants with adverse events [ Time Frame: Day 1 through to Day 14 ] [ Designated as safety issue: No ]

Enrollment: 14
Study Start Date: May 2012
Study Completion Date: July 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Metoprolol alone then eliglustat + metoprolol
In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
Drug: Eliglustat
Capsules for oral administration
Other Name: Genz-112638
Drug: Metoprolol
Tablets for oral administration
Other Name: Lopressor

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. The subject is willing and able to provide signed informed consent.
  2. The male or female subject is in good general health and between 18 and 40 years of age, inclusive.
  3. The subject has a body weight of 50 to 100 kg (110 to 220 lb) with a body mass index (BMI) ≤32 kg/m2 at screening.
  4. The subject's physical examination, laboratory, vital sign, and electrocardiogram (ECG) test results are within normal limits at screening and Day -1 or, if abnormal, are not considered clinically significant in the opinion of the Investigator.
  5. The subject has been a non-smoker for at least 6 months prior to the time of providing informed consent, and is willing and able to abstain from smoking (and use of other forms of nicotine) until completion of the safety follow-up visit.
  6. The subject has not used drugs of abuse for at least 6 months prior to Day -1 and is willing and able to abstain from using drugs of abuse until completion of the safety follow-up visit.
  7. The subject is willing and able to abstain from alcohol for 48 hours prior to the first dose of study drug until completion of the safety follow-up visit.
  8. The subject is willing and able to abstain from grapefruit, grapefruit juice or any other grapefruit-containing products for 72 hours prior to the first dose of study drug until completion of the safety follow-up visit.
  9. The subject is willing and able to maintain a normal-fiber diet (i.e., to abstain from excess fiber-rich foods) for 72 hours prior to the first dose of study drug until completion of the safety follow-up visit.
  10. Female subjects of childbearing potential must have a documented negative pregnancy test at screening, Day -1 and prior to dosing on Day 7 and be willing to use a medically accepted form of contraception (as defined in the protocol) from screening until 30 days after the last dose of study drug. A woman of childbearing potential is defined as any female who has not been amenorrheic for at least 2 years or has not undergone a hysterectomy or surgical sterilization.

Exclusion Criteria:

  1. The subject is classified as a cytochrome P450 2D6 (CYP2D6) poor metabolizer (or an indeterminate metabolizer with neither allele known to be active) based on results of CYP2D6 genotyping performed at screening. (Note: Prior CYP2D6 genotyping results may be used for the purpose of determining study eligibility if a copy of the laboratory report is available and the genotyping results can be interpreted with the same classification system used by the study reference laboratory.)
  2. The subject has a digestive disorder, including malabsorption, gastroenteritis, pancreatitis, gastroesophageal reflux disease, inflammatory bowel disease (including Crohn's disease), or any other digestive disorder which, in the opinion of the Investigator, may affect oral bioavailability (e.g., clinically significant constipation, diverticulitis, or irritable bowel syndrome).
  3. The subject has had a gastrointestinal (GI) surgical procedure that might affect drug transit time, (e.g., cholecystectomy, GI bypass surgery, partial or total gastrectomy, or small bowel resection).
  4. The subject has any of the following: Clinically significant coronary artery disease including history of myocardial infarction or ongoing signs or symptoms consistent with cardiac ischemia or heart failure; clinically significant arrhythmias or conduction defect such as 2nd or 3rd degree atrioventricular (AV) block, a PR interval ≥200 msec, complete bundle branch block, prolonged QTc interval (e.g., repeated demonstration of a QTc interval ≥430 msec for male subjects and ≥450 msec for female subjects), sustained ventricular tachycardia, heart rate <55 beats/min, or systolic blood pressure <110 mmHg.
  5. The subject has a clinically significant organic disease, including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic, or psychiatric disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, precludes participation in the trial.
  6. The subject has a disease, clinical finding, or any contraindication that would prohibit the use of metoprolol in a phase 1 study (i.e., risk of disease exacerbation outweighs benefit). Examples of these are clinical findings of glucose intolerance, poor arterial peripheral circulation or bronchospastic disease including asthma.
  7. The subject has a history of fainting, postural lightheadedness, or any other postural symptoms.
  8. The subject has received any prescription or non-prescription medication (with the exception of nonprescription-strength ibuprofen and acetaminophen, topical non-steroidal preparations, and topical hydrocortisone (up to 1% strength)) or dietary or herbal or fiber supplement within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug without the approval of both the Investigator and Sponsor.
  9. The subject has received an immunization within 30 days of providing informed consent.
  10. The subject has received an investigational product within 30 days prior to the first dose of study drug or plans to receive any other investigational product at any time during the course of this study.
  11. The subject has a history of drug allergies that are clinically significant in the opinion of the Investigator (e.g., significant rash or hives).
  12. The subject has a screening laboratory test result above the upper limit of normal for any of the following liver function tests: aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltransferase (GGT), and total bilirubin.
  13. The subject tests positive for human immunodeficiency virus (HIV) antibody, hepatitis C antibody, or hepatitis B surface antigen at screening.
  14. The subject tests positive for urine drugs of abuse, urine alcohol, or urine cotinine at screening.
  15. The subject donated blood or blood products within 30 days prior to providing informed consent.
  16. The subject's schedule or travel plans prevent the completion of all required visits.
  17. The subject is scheduled for inpatient hospitalization, including elective surgery (inpatient or outpatient), during the study.
  18. The subject has a history of cancer, with the exception of basal cell carcinoma.
  19. The female subject of childbearing potential is pregnant or lactating.
  20. The subject, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01659944

Locations
United States, Texas
Austin, Texas, United States
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Study Director: Medical Monitor Genzyme, a Sanofi Company
  More Information

No publications provided

Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT01659944     History of Changes
Other Study ID Numbers: GZGD04112
Study First Received: August 6, 2012
Last Updated: August 7, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Genzyme, a Sanofi Company:
Drug-drug interaction

Additional relevant MeSH terms:
Metoprolol
Metoprolol succinate
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014